Evidence map›Paper›PMID 23029095›Full record

ArticlePloS one2012

Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism.

Hyery Kim, Hyoung Jin Kang, Hyo Jeong Kim, Mi Kyung Jang, Nam Hee Kim, Yongtaek Oh, Byoung-Don Han, Ji-Yeob Choi, Chul Woo Kim, Ji Won Lee and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Pharmacogenomics and personalized medicine · 2021
    Article
  10. Review
  11. Pharmacogenetics of thiopurines.Cancer drug resistance (Alhambra, Calif.) · 2019
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Meta-analysis of the impact of thioprineOncoTargets and therapy · 2016
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Hyery KimDepartment of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Hyoung Jin Kang
Hyo Jeong Kim
Mi Kyung Jang
Nam Hee Kim
Yongtaek Oh
Byoung-Don Han
Ji-Yeob Choi
Chul Woo Kim
Ji Won Lee
Kyung Duk Park
Hee Young Shin
Hyo Seop Ahn
Seoul National University Hospital · KRKorea Yakult (South Korea) · KRSeoul National University · KRSNUH SMG-SNU Boramae Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic polymorphisms are important factors in the effects and toxicity of chemotherapeutics. To analyze the pharmacogenetic and ethnic differences in chemotherapeutics, major genes implicated in the treatment of acute lymphoblastic leukemia (ALL) were analyzed. Eighteen loci of 16 genes in 100 patients with ALL were analyzed. The distribution of variant alleles were CYP3A4*1B (0%), CYP3A5*3 (0%), GSTM1 (21%), GSTP1 (21%), GSTT1 (16%), MDR1 exon 21 (77%), MDR1 exon 26 (61%), MTHFR 677 (63%), MTHFR 1298 (29%), NR3C1 1088 (0%), RFC1 80 (68%), TPMT combined genotype (7%), VDR intron 8 (11%), VDR FokI (83%), TYMS enhancer repeat (22%) and ITPA 94 (30%). The frequencies of single nucleotide polymorphisms (SNPs) of 10 loci were statistically different from those in Western Caucasians. Dose percents (actual/planned dose) or toxicity of mercaptopurine and methotrexate were not related to any SNPs. Event free survival (EFS) rate was lower in ITPA variants, and ITPA 94 AC/AA variant genotypes were the only independent risk factor for lower EFS in multivariate analysis, which was a different pharmacogenetic implication from Western studies. This study is the first pharmacogenetic study in Korean pediatric ALL. Our result suggests that there are other possible pharmacogenetic factors besides TPMT or ITPA polymorphisms which influence the metabolism of mercaptopurine in Asian populations.

Indexed as

Polymorphism, Single NucleotideAdolescentAllelesAntineoplastic Combined Chemotherapy ProtocolsAsian PeopleChildChild, PreschoolFemaleGene FrequencyGenotypeHematopoietic Stem Cell TransplantationHumansInfantInosine TriphosphataseMaleMethyltransferasesInosine TriphosphataseITPA protein, humanMethyltransferasesPyrophosphatasesthiopurine methyltransferase

Identifiers

PMID23029095
PMCPMC3454425
OpenAlexW1982556402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.